Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

Milestone achievement triggers $15 million payment from collaborator

GlaxoSmithKline

CAMBRIDGE, Mass., Aug. 6 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today announced the initiation of a pivotal Phase 3 clinical trial that is evaluating otelixizumab in autoimmune new onset type 1 diabetes. As a result of the initiation of patient dosing in DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), Tolerx will receive a $15 million milestone payment from GlaxoSmithKline.

DEFEND is a randomized, placebo controlled Phase 3 trial designed to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at multiple centers in North America and Europe. The trial will evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will reduce the amount of administered insulin required to control blood glucose levels by inhibiting the destruction of beta cells. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function. Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, and a reduction in long-term disease complications in established type 1 diabetics in the Diabetes Control and Complications Trial (DCCT).

"We are excited to have dosed the first patient in DEFEND and look forward to continued patient enrollment in this Phase 3 clinical trial. The initiation of DEFEND represents the culmination of a methodical, dose-ranging development plan, including the successful outcome from an end-of-Phase 2 meeting at FDA. We believe otelixizumab has the potential to provide an important new treatment option for patients with newly dia
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 Reportlinker.com announces ... in its catalogue: Portugal Pharmaceuticals ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes ... View: Faster-than-expected economic growth last quarter has led ... slightly upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... , July 28, 2014  Serco Inc., ... announced the Company has been awarded a re-compete ... Command (NEMSCOM) and its Deployable Medical Systems.  Serco ... medical personnel to provide world-class healthcare to meet ... environment across the globe. The five year contract ...
(Date:7/28/2014)... , July 28, 2014  VigeneTech, Inc, in ... of LEGENDplex™ Data Analysis Software, an OEM software ... cytometers.  BioLegend develops and offers varieties of bead-based ... With the support of VigeneTech,s data analysis software, ... analyzed and easily reported LEGENDplex™ ...
Breaking Medicine Technology:Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 Camp ... a new camp property in Cornville, AZ. The ... ill children with the opportunity to attend medically ... and families. The organization offers a variety of ... with chronic and life threatening illnesses including: Illness ...
(Date:7/28/2014)... Quincy Bioscience, makers of the nation’s leading memory ... release of the fourth edition of The Brain Health ... , The Brain Health Guide is a unique resource ... to improve memory and promote optimal aging. Rather than ... Guide provides ways to help minimize common memory lapses ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... just milliseconds to look at someone,s face and judge them ... that certain facial features seem to trigger specific first impressions ... of the mouth, for example, appear directly linked to whether ... The study findings suggest that first impressions are ...
(Date:7/28/2014)... TX (PRWEB) July 28, 2014 Ticket ... vs. AS Roma tickets in Dallas, TX at the ... July 24th in the USA and it is an eight ... from around the world including teams from La Liga, Serie ... teams that will battle it out on the pitch include: ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Glutamine is ... and it’s considered to be conditionally essential during times ... is an advanced recovery & Immune System Support. , ... glutamine your body produces, supplementing with additional glutamine may ... waste products in the body, digestion and immune system ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... Jolt of java better than a nap to prevent mistakes, ... news for javaholics: A new review suggests that caffeine consumption ... 15 percent of workers in industrialized countries are thought to ... can disrupt their body clocks. Some suffer from shift-work disorder, ...
... trouble, experts say , WEDNESDAY, May 12 (HealthDay News) -- ... maintain could make life better for people who rely on ... defibrillator delivers an electric shock to restart a heart that ... Americans each year. Current models require careful surgery to run ...
... a significant predictor of responses to vaccines, according to ... Health. They examined published data from numerous adult and ... fundamental, but often overlooked predictor of vaccine response that ... The review is featured in the May 2010 issue ...
... Medical Researchers at the University of Alberta reported today evidence ... as potential therapy for perhaps the deadliest of all human ... is published at the journal Science Translational Medicine , ... Science; it appears today at the journal,s web site ...
... Researchers at Queen,s University have developed a new ... the way doctors manage prostate cancer treatment. It will ... a gene called PTEN that is associated with an ... In-Situ Hybridization (FISH) platform uses DNA probes to analyze ...
... ... Expansion of Their Candy Store, bwcliffordcandy.com with New Products, Industry Related News and Educational ... , ... 2010 -- BW Clifford proudly announces the expansion of their candy store , ...
Cached Medicine News:Health News:New Implanted Defibrillator May Be Simpler, Safer 2Health News:New Implanted Defibrillator May Be Simpler, Safer 3Health News:Response to vaccines could depend on your sex 2Health News:DCA research on brain cancer 2Health News:DCA research on brain cancer 3Health News:Online Candy Store BW Clifford Launches New Candy Lines and Industry News Resources 2
Inquire...
... a powerful PTFE membrane vacuum pump designed to ... Ideally suited for use with up to two ... instruments including vacuum ovens, concentrators, gel dryers, and ... PEEK head resistant to chemicals and heat load ...
... pumps deliver critical performance for all vacuum ... optimizes pump performance to suit all applications. ... convenient checking of proper oil levels at ... is designed to work with all Thermo ...
... two-stage, oil-sealed, rotary vane vacuum pumps specifically ... pump comes complete with a GBORK (Gas ... Mist Filter (EMF-10). The GBORK allows the ... keep the oil clean without losing oil. ...
Medicine Products: